Stay updated on T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page.

Latest updates to the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.1 to version 2.15.2.SummaryDifference0.0%
- Check14 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.1.SummaryDifference0.0%
- Check22 days agoChange DetectedThe webpage has undergone significant updates regarding a clinical study on trastuzumab deruxtecan, including the addition of new identifiers and a description of the study's treatment arms, while removing detailed eligibility criteria and study objectives.SummaryDifference12%
- Check29 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4, indicating a new release. Additionally, the previous estimated timestamps for 'Results First Posted' and 'Last Update Posted' have been removed.SummaryDifference0.1%
- Check36 days agoChange DetectedThe web page has been updated to include detailed assessments of Progression-Free Survival (PFS) and Overall Survival (OS) in various populations, with specific methodologies and timelines for evaluations. Additionally, there are new definitions and metrics for Objective Response Rate (ORR) and Duration of Response (DOR), enhancing the clarity and comprehensiveness of the clinical study results.SummaryDifference61%
- Check43 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, replacing the previous estimated date of January 15, 2025.SummaryDifference0.1%
Stay in the know with updates to T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page.